# Retatrutide: research overview | Peptide Research Alliance > Retatrutide (LY3437943) is an investigational GIP/GLP-1/glucagon triple agonist in Phase 3 trials. Plain-English summary of mechanism, Phase 2 findings, community reports, and safety cautions. An investigational triple-incretin receptor agonist. Not yet approved. Here is what the published trials show — and where community experience diverges. ## The short version Retatrutide (also known as LY3437943) is a synthetic peptide being studied by Eli Lilly as a treatment for obesity and type 2 diabetes. It is in Phase 3 clinical trials as of mid-2026 and has not been approved by the FDA or any other regulatory agency. What makes it unusual is that it activates three hormone receptors at once — the GLP-1 receptor, the GIP receptor, and the glucagon receptor. This *triple agonism* (not "GLP-3," a term sometimes used informally but considered a misnomer by researchers) drives larger weight reduction than single or dual agents in studies so far. The largest Phase 2 trial showed a mean of around **24% body-weight reduction** at the highest dose over 48 weeks [4]. It is administered once weekly by injection and has a roughly 6-day half-life [6]. The most common side effects in trials were gastrointestinal — nausea, vomiting, diarrhea — and heart rate increased modestly at higher doses [4]. Long-term outcomes data do not yet exist; dedicated trials are ongoing. Any retatrutide sold outside a clinical trial is unverified material operating outside any regulatory oversight. ## What it is Retatrutide is a 39-amino-acid synthetic peptide built on a GIP-based backbone, with a C20 fatty-diacid acylation that enables albumin binding and an extended half-life supporting weekly dosing. Its full name in Eli Lilly's program is LY3437943; other names sometimes seen in community discussion include "GGG tri-agonist" and "triple agonist (GIP/GLP-1/glucagon)." It is an **investigational drug** — meaning it can legally be administered only under a clinical-trial protocol or under FDA-regulated access pathways. It is not a prescription medicine; no approved labeling exists. Material sold as "retatrutide research chemical" is unregulated and has no verified identity, purity, or sterility. ## How it works Retatrutide engages three receptors simultaneously: - **GLP-1 receptor (GLP-1R):** Suppresses appetite and improves insulin secretion in a glucose-dependent manner. - **GIP receptor (GIPR):** Further amplifies insulin secretion and, at high activation levels, may also suppress appetite. Cryo-EM structural data show retatrutide is approximately 8.9× more potent at GIPR than native GIP [2]. - **Glucagon receptor (GCGR):** Adds energy expenditure via thermogenic mechanisms and promotes hepatic lipid mobilization — the component thought to differentiate retatrutide from dual-agonist approaches. The three arms together drive weight loss by suppressing intake (GLP-1R, GIPR) while simultaneously raising energy expenditure (GCGR), a combination that accounts for larger weight reductions than either effect alone [1]. Controlled glucagon-receptor activation also appears to drive the dose-dependent increase in resting heart rate documented in Phase 2 trials [4]. ## What the research shows **Phase 1 (first-in-human, 2022):** In 72 adults with type 2 diabetes, retatrutide demonstrated a half-life of approximately 6 days, confirming once-weekly dosing. The highest-dose group lost 8.96 kg placebo-adjusted over 12 weeks — notable for a Phase 1 study. Gastrointestinal adverse events were the most common treatment-emergent effect, occurring in 63% of participants [6]. **Phase 2 — obesity (2023):** In 338 adults with obesity, once-weekly retatrutide over 48 weeks produced a mean body-weight change of **−24.2% at the 12 mg dose** versus −2.1% for placebo. GI adverse events were dose-related and mostly mild-to-moderate. A dose-dependent heart-rate increase peaked around week 24 [4]. **Phase 2 — type 2 diabetes (2023):** In 281 adults with T2D, the 12 mg dose reduced HbA1c by −2.02% at 24 weeks and body weight by −16.94% at 36 weeks. No severe hypoglycemia or deaths were reported [5]. **Phase 2 — liver fat (2024):** In 98 participants with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), the 12 mg dose reduced liver fat by −82.4% at 24 weeks, with 86% of participants reaching normal liver-fat levels (<5%) [3]. **Structural biology (2024):** Cryo-EM resolved retatrutide bound to all three receptor complexes simultaneously (at 2.68/3.26/2.84 Å), confirming true triple agonism at the molecular level [2]. **Metabolomics post-hoc (2026):** Analysis of Phase 2 samples from ~495 participants found that higher doses reduced triglycerides and improved biomarkers of insulin resistance (branched-chain amino acids, 2-hydroxybutyrate, urate) in directions associated with reduced cardiovascular risk. Changes in a fatty-acid-oxidation metabolite cluster mediated 23.2% of the weight-reduction response in participants without T2D [7]. **2025 review:** A narrative synthesis characterized retatrutide's ~24% weight loss as a step-change versus prior incretin therapies and described the ongoing Phase 3 TRIUMPH program [1]. ## Reported effects, cautions & safety **What research-use communities report** *(anecdotal, not clinical evidence — these are unverified self-reports from people using unregulated material with no confirmed doses or clinical oversight)* The most frequently described benefits are a near-total quieting of food preoccupation ("food noise going quiet") and rapid, pronounced weight reduction — reports align broadly with trial trajectories. A commonly noted phenomenon is a mild thermogenic warmth, widely attributed in community discussion to glucagon-receptor-mediated energy expenditure. On the adverse side, nausea is the most commonly described experience, especially in the early weeks and after dose escalations. Community members also frequently report elevated resting heart rate detectable on wearables, sulfur burps from slowed gastric motility, fatigue in the first weeks, and constipation. Less common reports include injection-site itching, sleep disturbances, and lean-mass loss concern among those tracking body composition. **Safety cautions from the clinical literature:** *Supply and regulatory status:* Retatrutide has not been approved. Material obtained outside clinical trials cannot be confirmed to contain authentic retatrutide at stated concentration; unregulated peptide products have been found to contain truncated sequences or entirely different compounds. The FDA issued over 50 warning letters to retatrutide vendors in 2025 [4]. *Gastrointestinal events:* Nausea affected up to 45% of participants at the highest Phase 2 dose and was the principal driver of the 18% discontinuation rate at that level [4]. Dehydration and electrolyte imbalance are realistic risks in unmonitored contexts. *Heart rate:* Phase 2 data show dose-dependent mean heart-rate increases of approximately 5–7 bpm, peaking around 24 weeks [4]. A cardiovascular outcomes trial (NCT06383390) is ongoing and has not reported results [1]. *Drug interactions:* Retatrutide's GLP-1 and GIP agonism augments insulin secretion; in people already on insulin or sulfonylureas, this combination may drive blood glucose below safe thresholds. Phase 2 diabetic participants on background insulin required insulin dose reduction during the trial [5]. *Lean mass:* The compound reduces lean body mass in absolute terms alongside fat mass; the 2025 Lancet Diabetes & Endocrinology body-composition substudy confirmed this in T2D participants. The clinical significance increases with age and in those with sarcopenic risk [1]. *Unknown long-term outcomes:* The TRIUMPH series and dedicated cardiovascular/kidney outcome trials remain ongoing. No long-term outcomes data exist; weight regain after discontinuation appears likely based on analogous GLP-1-class agents [1]. ## Where it fits Among the five compounds covered on this desk, retatrutide is the one with the most robust and recent human trial evidence — multiple Phase 2 RCTs, a structural-biology dataset, and an active Phase 3 program. It is also the furthest from any consumer's reach in a legitimate sense: it is an investigational drug, not a supplement or an approved prescription. Its triple-agonist mechanism puts it in a pharmacological category of its own relative to the other metabolic-adjacent compounds discussed here. It is meaningfully different from dual agonists, and the informal "GLP-3" label that sometimes appears in community discussion is technically inaccurate — glucagon was long part of the incretin literature, but it does not map to a "GLP-3" designation. For readers following this compound: the Phase 3 TRIUMPH program is the authoritative ongoing source of efficacy data. Published peer-reviewed trial results — not community reports or vendor claims — are the only reliable way to track where the science stands. --- An independent literature desk where every enthusiastic claim is immediately grounded in a citation and every gap in the evidence is stated plainly.